Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Presc… (NCT07202377) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
200 participantsStarted 2025-10
Plain-language summary
Evaluate the impact of rapid, real-time (4 to 6 h) MIC reporting compared with the standard method (=diffusion antibiotic susceptibility testing) (18 to 24 h) on β-lactam prescribing in terms of the choice of molecule by the resuscitating clinician in the event of real-life Gram-negative Bacilli GNB bacteremia in the ICU.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients aged over 18 years
* Patients with a positive blood culture for Gram-negative bacilli (Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii) with results reported on weekdays before 11:00 ante meridiem (AM)
* Patients clinically suspected of infection
* Treated with empirical antibiotic therapy including a β-lactam, among the standard list of antibiotics to be tested recommended by CASFM-EUCAST (European Committee on Antimicrobial Susceptibility Testing) for Enterobacterales/Pseudomonas and included in the Reveal Rapid AST System panel
* Hospitalized in intensive care unit (ICU) for at least the next 24 hours
* Written informed consent obtained from the patient or a relative for study participation (emergency consent)
* Affiliated with the French social security system
Exclusion Criteria:
* Patients receiving withdrawal or limitation of care
* Patients with an expected survival prognosis of less than 72 hours
* Patients with bloodstream infections caused by Gram-negative bacilli other than Acinetobacter baumannii, Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa
* Patients treated with antibiotic therapy not including a β-lactam
* Polymicrobial bloodstream infections
* Pregnant or breastfeeding women
* Patients under legal protection (guardianship or conservatorship)
* Participation …
What they're measuring
1
Proportion of patients for whom antibiotic therapy was modified in terms of molecule selection within the first 24 hours following the report of a positive blood culture for Gram-negative bacilli, based on medical prescriptions after inclusion
Timeframe: 24 hours following the report of a positive blood culture for Gram-negative bacilli